


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-45. Canceled.

46. (Previously Presented) A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:




wherein R<sup>1</sup> and R<sup>3</sup> are each independently selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic.


47. (Previously Presented) A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor or a pharmaceutically acceptable salt thereof is selected from the group consisting of a compounds recited in Table I as:

number (nb) 20, number (nb) 21, number (nb) 22, number (nb) 23, number (nb) 36,  
number (nb) 38, number (nb) 44, number (nb) 53, number (nb) 57, number (nb) 58,  
number (nb) 59, number (nb) 60, number (nb) 65, number (nb) 66, number (nb) 67,  
number (nb) 75, number (nb) 100, number (nb) 103, number (nb) 104, number (nb) 105,  
number (nb) 108, number (nb) 118, number (nb) 119, number (nb) 124, number (nb) 125,

number (nb) 126, number (nb) 128, number (nb) 140, number (nb) 143, number (nb) 148,  
number (nb) 151, number (nb) 153, number (nb) 156, number (nb) 157, number (nb) 159,  
number (nb) 167, number (nb) 168, number (nb) 169, number (nb) 170, number (nb) 172,  
number (nb) 175, number (nb) 176, number (nb) 178, number (nb) 179, number (nb) 180,  
number (nb) 181, number (nb) 183, number (nb) 188, number (nb) 189, number (nb) 192,  
number (nb) 193, number (nb) 253, number (nb) 257, number (nb) 270, number (nb) 283,  
number (nb) 286, number (nb) 287, number (nb) 297, number (nb) 299, number (nb) 341,  
number (nb) 343, number (nb) 344, number (nb) 347, number (nb) 354, number (nb) 358,  
number (nb) 359, number (nb) 360, number (nb) 361, number (nb) 362, number (nb) 375,  
number (nb) 377, number (nb) 379, number (nb) 380, number (nb) 384, number (nb) 385,  
number (nb) 411, number (nb) 412, number (nb) 413, number (nb) 425, number (nb) 427,  
number (nb) 428, number (nb) 429, number (nb) 430, number (nb) 434, number (nb) 435,  
number (nb) 437, number (nb) 438, number (nb) 461, number (nb) 463, number (nb) 470,  
number (nb) 471, number (nb) 473, number (nb) 477, number (nb) 478, number (nb) 479,  
number (nb) 501, number (nb) 504, number (nb) 508, number (nb) 509, number (nb) 531,  
number (nb) 533, number (nb) 538, number (nb) 543, number (nb) 544, number (nb) 545,  
number (nb) 551, number (nb) 556, number (nb) 559, number (nb) 562,




48. (Previously Presented) A method of reducing hypertension in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor or a pharmaceutically acceptable salt thereof is a compound having a structure of:



wherein R<sup>1</sup> and R<sup>3</sup> are each independently selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic.

49. (Previously Presented) A method of reducing hypertension in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor or a pharmaceutically acceptable salt thereof of soluble epoxide hydrolase, wherein said inhibitor is selected from the group consisting of a compounds recited in Table I as:

number (nb) 20, number (nb) 21, number (nb) 22, number (nb) 23, number (nb) 36,  
number (nb) 38, number (nb) 44, number (nb) 53, number (nb) 57, number (nb) 58,  
number (nb) 59, number (nb) 60, number (nb) 65, number (nb) 66, number (nb) 67,  
number (nb) 75, number (nb) 100, number (nb) 103, number (nb) 104, number (nb) 105,  
number (nb) 108, number (nb) 118, number (nb) 119, number (nb) 124, number (nb) 125,  
number (nb) 126, number (nb) 128, number (nb) 140, number (nb) 143, number (nb) 148,  
number (nb) 151, number (nb) 153, number (nb) 156, number (nb) 157, number (nb) 159,  
number (nb) 167, number (nb) 168, number (nb) 169, number (nb) 170, number (nb) 172,  
number (nb) 175, number (nb) 176, number (nb) 178, number (nb) 179, number (nb) 180,  
number (nb) 181, number (nb) 183, number (nb) 188, number (nb) 189, number (nb) 192,  
number (nb) 193, number (nb) 253, number (nb) 257, number (nb) 270, number (nb) 283,  
number (nb) 286, number (nb) 287, number (nb) 297, number (nb) 299, number (nb) 341,  
number (nb) 343, number (nb) 344, number (nb) 347, number (nb) 354, number (nb) 358,  
number (nb) 359, number (nb) 360, number (nb) 361, number (nb) 362, number (nb) 375,  
number (nb) 377, number (nb) 379, number (nb) 380, number (nb) 384, number (nb) 385,  
number (nb) 411, number (nb) 412, number (nb) 413, number (nb) 425, number (nb) 427,  
number (nb) 428, number (nb) 429, number (nb) 430, number (nb) 434, number (nb) 435,  
number (nb) 437, number (nb) 438, number (nb) 461, number (nb) 463, number (nb) 470,  
number (nb) 471, number (nb) 473, number (nb) 477, number (nb) 478, number (nb) 479,  
number (nb) 501, number (nb) 504, number (nb) 508, number (nb) 509, number (nb) 531,  
number (nb) 533, number (nb) 538, number (nb) 543, number (nb) 544, number (nb) 545,  
number (nb) 551, number (nb) 556, number (nb) 559, number (nb) 562,



50. (Previously Presented) The method according to claim 46, wherein said inhibitor inhibits soluble epoxide hydrolase enzymatic activity with an  $IC_{50}$  of less than 500  $\mu M$ .

51. (Previously Presented) The method according to claim 46, wherein said inhibitor inhibits soluble epoxide hydrolase enzymatic activity with an  $IC_{50}$  of less than 17.8  $\mu M$ .

52. (Previously Presented) The method according to claim 48, wherein said inhibitor inhibits soluble epoxide hydrolase enzymatic activity with an  $IC_{50}$  of less than 500  $\mu M$ .

53. (Previously Presented) The method according to claim 48, wherein said inhibitor inhibits soluble epoxide hydrolase enzymatic activity with an  $IC_{50}$  of less than 17.8  $\mu M$ .